Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: A multicenter study

Journal of Clinical Pharmacology

Volumn 52, Issue 3, 2012, Pages 425-431

  Xiong, Chang Ming ^a   Lu, Xian Ling ^a   Shan, Guang Liang ^b   Wu, Bing Xiang ^c   Zhu, Xian Yang ^d   Wu, Guang Hua ^e   Zeng, Xiao Feng ^f   Guo, Tao ^g   Liu, Zhi Hong ^a   Ni, Xin Hai ^a   Cheng, Xian Sheng ^a   Gu, Qing ^a   Zhao, Zhi Hui ^a   Tian, Hong Yan ^h   Li, Wei Min ^c   Zhang, Duan Zhen ^d   Zhang, Cheng ^e   Li, Meng Tao ^f   Liu, Hong Min ^g   Guo, Ya Juan ^h   Shen, Jie Yan ⁱ   Zhang, Wei Jun ^j   Liu, Shuang ^j   Zhou, Da Xin ^k   Bao, Chun De ⁱ   Huang, Shi An ^l   Chen, Jian Ying ^l   Wu, Wei Feng ^m   Huang, Kai ^m   Li, Chang Ling ⁿ   Wang, Li Hua ⁿ   He, Bei ^a   He, Jian Guo ^o   Li, Jian Jun ^a   more..

^a FUWAI HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^e JINING MEDICAL UNIVERSITY   (China)

^f PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^g KUNMING MEDICAL UNIVERSITY   (China)

^h XI'AN JIAOTONG UNIVERSITY   (China)

ⁱ SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^j CAPITAL MEDICAL UNIVERSITY   (China)

^k ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^l GUANGDONG MEDICAL UNIVERSITY   (China)

^m GUANGXI MEDICAL UNIVERSITY   (China)

ⁿ ZHEJIANG UNIVERSITY   (China)

^o PEKING UNIVERSITY THIRD HOSPITAL   (China)

more..

Author keywords

phosphodiesterase inhibitors; pulmonary arterial hypertension; Sildenafil

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CHINESE; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; FLUSHING; HEADACHE; HEART CATHETERIZATION; HUMAN; INDIGESTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PULMONARY HYPERTENSION; SIDE EFFECT; SIX MINUTE WALK TEST; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; WALKING;

ADMINISTRATION, ORAL; ADULT; CHINA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; PURINES; SULFONES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84860148526     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011398241     Document Type: Article

References (23)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 ; 43 (suppl 12). 5S - 12S
2. Humbert M, Sitbon O, Simonneau G. Drug therapy: treatment of pulmonary arterial hypertension. N Engl J Med. 2004 ; 351: 1425-1436
3. Kuhn KP, Byrne QW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003 ; 167: 580-586
4. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 ; 346: 896-903
5. Kataoka M, Satoh T, Manabe T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J. 2005 ; 69: 461-465
6. Sastry BKS, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension-a randomized, placebo controlled, double blind, crossover study. J Am Coll Cardiol. 2004 ; 43: 1149-1153
7. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353: 2148-2157
8. Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol. 2007 ; 120: 306-313
9. Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005 ; 100: 267-273
10. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007 ; 120: 301-305
11. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 ; 34: 2417-2422
12. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 ; 25: 2243-2278
13. ATS statement: guidelines foe the six-minute walk test. Am J Respir Crit Care Med. 2002 ; 166: 111-117
14. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005 ; 112: 828-835
15. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002 ; 106: 319-324
16. Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol. 1999 ; 84: 677-681
17. Pacilcco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001 ; 17: 647-652
18. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000 ; 161: 486-492
19. Corbin JD, Francis SH. Cyclic GMP phosphodieserase-5: target of sildenafil. J Biol Chem. 1999 ; 274: 13729-13732
20. Sanchez LS, de la Monte SM, Filippov G, et al. Cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res. 1998 ; 43: 163-168
21. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology. 2000 ; 92: 1702-1712
22. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med. 2000 ; 343: 1342
23. Chochalingam A, Gnanavelu G, Venkatesen S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol. 2005 ; 99: 91-95